SLC5A2 and type 1 diabetes mellitus: Dapagliflozin, a highly selective SGLT2 inhibitor, has demonstrated therapeutic benefits in individuals with type 1 diabetes by reducing postprandial glucose concentrations, albuminuria and blood pressure, along with promoting weight loss [1–3].